Alan Cantor

Alan Cantor, MD, PhD

Assistant in Medicine

Associate Professor of Pediatrics, Harvard Medical School

  • Contact: 617-919-2026

  • Fax: 617-730-0222

Medical Services

Specialties

  • Hematology Oncology

Departments

  • Hematology / Oncology
  • Medicine

Programs

  • Bone Marrow Failure Program
  • Hematology / Oncology
To schedule an appointment: Call 617-919-2026 or Request an Appointment

Experience and Education

Education

Washington University School of Medicine, PhD 1993

St. Louis , MO

Washington University School of Medicine, 1993

St. Louis, MO

Pediatrics

Saint Louis Children's Hospital, 07/94 to 06/96

St. Louis, MO

Undergraduate School

Cornell University, grad. 1985

Ithaca , NY

Pediatric Hematology/Oncology

Children's Hospital Boston/Dana-Farber Cancer Institute, 07/96 to 06/98

Boston, MA

Certifications

  • Pediatric Hematology/Oncology

Publications

Publications powered by Harvard Catalyst Profiles
  1. Wyszynski DF, Carman WJ, Cantor AB, Graham JM, Kunz LH, Slavotinek AM, Kirby RS, Seeger J. Pregnancy and Birth Outcomes among Women with Idiopathic Thrombocytopenic Purpura. J Pregnancy. 2016; 2016:8297407.
  2. Leong WY, Guo H, Ma O, Huang H, Cantor AB, Friedman AD. Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis. J Biol Chem. 2016 Jan 8; 291(2):826-36.
  3. Walsh SB, Varma R, Raimer D, Keane JC, Cantor A, Theos A, Northington M, Huang CC. Utility of Wood's light in margin determination of melanoma in situ after excisional biopsy. Dermatol Surg. 2015 May; 41(5):572-8.
  4. Chung J, Bauer DE, Ghamari A, Nizzi CP, Deck KM, Kingsley PD, Yien YY, Huston NC, Chen C, Schultz IJ, Dalton AJ, Wittig JG, Palis J, Orkin SH, Lodish HF, Eisenstein RS, Cantor AB, Paw BH. The mTORC1/4E-BP pathway coordinates hemoglobin production with L-leucine availability. Sci Signal. 2015; 8(372):ra34.
  5. Gao R, Chen S, Kobayashi M, Yu H, Zhang Y, Wan Y, Young SK, Soltis A, Yu M, Vemula S, Fraenkel E, Cantor A, Antipin Y, Xu Y, Yoder MC, Wek RC, Ellis SR, Kapur R, Zhu X, Liu Y. Bmi1 promotes erythroid development through regulating ribosome biogenesis. Stem Cells. 2015 Mar; 33(3):925-38.
  6. Herrmann JL, Cunningham R, Cantor A, Elewski BE, Elmets CA. Tanning accelerators: prevalence, predictors of use, and adverse effects. J Am Acad Dermatol. 2015 Jan; 72(1):99-104.
  7. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr; 17(4):596-603.
  8. Yien YY, Robledo RF, Schultz IJ, Takahashi-Makise N, Gwynn B, Bauer DE, Dass A, Yi G, Li L, Hildick-Smith GJ, Cooney JD, Pierce EL, Mohler K, Dailey TA, Miyata N, Kingsley PD, Garone C, Hattangadi SM, Huang H, Chen W, Keenan EM, Shah DI, Schlaeger TM, DiMauro S, Orkin SH, Cantor AB, Palis J, Koehler CM, Lodish HF, Kaplan J, Ward DM, Dailey HA, Phillips JD, Peters LL, Paw BH. TMEM14C is required for erythroid mitochondrial heme metabolism. J Clin Invest. 2014 Oct; 124(10):4294-304.
  9. Bag AK, Cezayirli PC, Davenport JJ, Gaddikeri S, Fathallah-Shaykh HM, Cantor A, Han XS, Nabors LB. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters. J Neurooncol. 2014 Nov; 120(2):361-70.
  10. McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017. Ann Surg Oncol. 2015 Jan; 22(1):75-81.
  11. Show all
  12. Weiss B, Widemann BC, Wolters P, Dombi E, Vinks AA, Cantor A, Korf B, Perentesis J, Gutmann DH, Schorry E, Packer R, Fisher MJ. Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer. 2014 Jun; 61(6):982-6.
  13. Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol Ther. 2014 May; 22(5):1048-55.
  14. Griguer CE, Cantor AB, Fathallah-Shaykh HM, Gillespie GY, Gordon AS, Markert JM, Radovanovic I, Clement-Schatlo V, Shannon CN, Oliva CR. Prognostic relevance of cytochrome C oxidase in primary glioblastoma multiforme. PLoS One. 2013; 8(4):e61035.
  15. Blair CK, Madan-Swain A, Locher JL, Desmond RA, de Los Santos J, Affuso O, Glover T, Smith K, Carley J, Lipsitz M, Sharma A, Krontiras H, Cantor A, Demark-Wahnefried W. Harvest for health gardening intervention feasibility study in cancer survivors. Acta Oncol. 2013 Aug; 52(6):1110-8.
  16. De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer. 2013 May 15; 119(10):1776-83.
  17. Cody JJ, Scaturro P, Cantor AB, Yancey Gillespie G, Parker JN, Markert JM. Preclinical evaluation of oncolytic d?(1)34.5 herpes simplex virus expressing interleukin-12 for therapy of breast cancer brain metastases. Int J Breast Cancer. 2012; 2012:628697.
  18. Andriole GL, McCullum-Hill C, Sandhu GS, Crawford ED, Barry MJ, Cantor A. The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trial. J Urol. 2013 Feb; 189(2):486-92.
  19. Cantor AB. Dynamin 3 and platelet size variation. Blood. 2012 Dec 6; 120(24):4666-7.
  20. Barry MJ, Cantor A, Roehrborn CG. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. J Urol. 2013 Mar; 189(3):987-92.
  21. Huang H, Woo AJ, Waldon Z, Schindler Y, Moran TB, Zhu HH, Feng GS, Steen H, Cantor AB. A Src family kinase-Shp2 axis controls RUNX1 activity in megakaryocyte and T-lymphocyte differentiation. Genes Dev. 2012 Jul 15; 26(14):1587-601.
  22. Cantor AB. Death-defying apoptotic caspases in thrombopoiesis. Blood. 2012 May 3; 119(18):4098-9.
  23. Yu M, Mazor T, Huang H, Huang HT, Kathrein KL, Woo AJ, Chouinard CR, Labadorf A, Akie TE, Moran TB, Xie H, Zacharek S, Taniuchi I, Roeder RG, Kim CF, Zon LI, Fraenkel E, Cantor AB. Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors. Mol Cell. 2012 Feb 10; 45(3):330-43.
  24. Yu M, Cantor AB. Megakaryopoiesis and thrombopoiesis: an update on cytokines and lineage surface markers. Methods Mol Biol. 2012; 788:291-303.
  25. Barry MJ, Meleth S, Lee JY, Kreder KJ, Avins AL, Nickel JC, Roehrborn CG, Crawford ED, Foster HE, Kaplan SA, McCullough A, Andriole GL, Naslund MJ, Williams OD, Kusek JW, Meyers CM, Betz JM, Cantor A, McVary KT. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011 Sep 28; 306(12):1344-51.
  26. De Los Santos J, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, Cantor A, Forero A. Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. Clin Breast Cancer. 2011 Oct; 11(5):312-9.
  27. Woo AJ, Kim J, Xu J, Huang H, Cantor AB. Role of ZBP-89 in human globin gene regulation and erythroid differentiation. Blood. 2011 Sep 29; 118(13):3684-93.
  28. Costa FP, de Oliveira AC, Meirelles R, Machado MC, Zanesco T, Surjan R, Chammas MC, de Souza Rocha M, Morgan D, Cantor A, Zimmerman J, Brezovich I, Kuster N, Barbault A, Pasche B. Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields. Br J Cancer. 2011 Aug 23; 105(5):640-8.
  29. Filiano AN, Fathallah-Shaykh HM, Fiveash J, Gage J, Cantor A, Kharbanda S, Johnson MR. Gene expression analysis in radiotherapy patients and C57BL/6 mice as a measure of exposure to ionizing radiation. Radiat Res. 2011 Jul; 176(1):49-61.
  30. Amigo JD, Yu M, Troadec MB, Gwynn B, Cooney JD, Lambert AJ, Chi NC, Weiss MJ, Peters LL, Kaplan J, Cantor AB, Paw BH. Identification of distal cis-regulatory elements at mouse mitoferrin loci using zebrafish transgenesis. Mol Cell Biol. 2011 Apr; 31(7):1344-56.
  31. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010 Oct 15; 143(2):313-24.
  32. Rossman J, Reddy V, Cantor A, Miley D, Robert F. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer. Lung Cancer. 2011 May; 72(2):219-23.
  33. Bai X, Kim J, Yang Z, Jurynec MJ, Akie TE, Lee J, LeBlanc J, Sessa A, Jiang H, DiBiase A, Zhou Y, Grunwald DJ, Lin S, Cantor AB, Orkin SH, Zon LI. TIF1gamma controls erythroid cell fate by regulating transcription elongation. Cell. 2010 Jul 9; 142(1):133-43.
  34. Grunda JM, Fiveash J, Palmer CA, Cantor A, Fathallah-Shaykh HM, Nabors LB, Johnson MR. Rationally designed pharmacogenomic treatment using concurrent capecitabine and radiotherapy for glioblastoma; gene expression profiles associated with outcome. Clin Cancer Res. 2010 May 15; 16(10):2890-8.
  35. Yu M, Riva L, Xie H, Schindler Y, Moran TB, Cheng Y, Yu D, Hardison R, Weiss MJ, Orkin SH, Bernstein BE, Fraenkel E, Cantor AB. Insights into GATA-1-mediated gene activation versus repression via genome-wide chromatin occupancy analysis. Mol Cell. 2009 Nov 25; 36(4):682-95.
  36. Amigo JD, Ackermann GE, Cope JJ, Yu M, Cooney JD, Ma D, Langer NB, Shafizadeh E, Shaw GC, Horsely W, Trede NS, Davidson AJ, Barut BA, Zhou Y, Wojiski SA, Traver D, Moran TB, Kourkoulis G, Hsu K, Kanki JP, Shah DI, Lin HF, Handin RI, Cantor AB, Paw BH. The role and regulation of friend of GATA-1 (FOG-1) during blood development in the zebrafish. Blood. 2009 Nov 19; 114(21):4654-63.
  37. Huang H, Cantor AB. Common features of megakaryocytes and hematopoietic stem cells: what's the connection? J Cell Biochem. 2009 Aug 1; 107(5):857-64.
  38. Huang H, Yu M, Akie TE, Moran TB, Woo AJ, Tu N, Waldon Z, Lin YY, Steen H, Cantor AB. Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development. Mol Cell Biol. 2009 Aug; 29(15):4103-15.
  39. Kim J, Cantor AB, Orkin SH, Wang J. Use of in vivo biotinylation to study protein-protein and protein-DNA interactions in mouse embryonic stem cells. Nat Protoc. 2009; 4(4):506-17.
  40. Wang J, Cantor AB, Orkin SH. Tandem affinity purification of protein complexes in mouse embryonic stem cells using in vivo biotinylation. Curr Protoc Stem Cell Biol. 2009 Mar; Chapter 1:Unit1B.5.
  41. Sankaran VG, Menne TF, Xu J, Akie TE, Lettre G, Van Handel B, Mikkola HK, Hirschhorn JN, Cantor AB, Orkin SH. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008 Dec 19; 322(5909):1839-42.
  42. Hawley RG, Hawley TS, Cantor AB. TLX1 (HOX11) immortalization of embryonic stem cell-derived and primary murine hematopoietic progenitors. Curr Protoc Stem Cell Biol. 2008 Dec; Chapter 1:Unit 1F.7.
  43. Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1112-8.
  44. Cantor AB, Iwasaki H, Arinobu Y, Moran TB, Shigematsu H, Sullivan MR, Akashi K, Orkin SH. Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med. 2008 Mar 17; 205(3):611-24.
  45. Woo AJ, Moran TB, Schindler YL, Choe SK, Langer NB, Sullivan MR, Fujiwara Y, Paw BH, Cantor AB. Identification of ZBP-89 as a novel GATA-1-associated transcription factor involved in megakaryocytic and erythroid development. Mol Cell Biol. 2008 Apr; 28(8):2675-89.
  46. Lengacher CA, Bennett MP, Gonzalez L, Gilvary D, Cox CE, Cantor A, Jacobsen PB, Yang C, Djeu J. Immune responses to guided imagery during breast cancer treatment. Biol Res Nurs. 2008 Jan; 9(3):205-14.
  47. Fishman M, Hunter TB, Soliman H, Thompson P, Dunn M, Smilee R, Farmelo MJ, Noyes DR, Mahany JJ, Lee JH, Cantor A, Messina J, Seigne J, Pow-Sang J, Janssen W, Antonia SJ. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008 Jan; 31(1):72-80.
  48. Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul 1; 25(19):2741-6.
  49. Johnson KD, Boyer ME, Kang JA, Wickrema A, Cantor AB, Bresnick EH. Friend of GATA-1-independent transcriptional repression: a novel mode of GATA-1 function. Blood. 2007 Jun 15; 109(12):5230-3.
  50. Engelman RW, Jackson RJ, Coppola D, Wharton W, Cantor AB, Pledger WJ. Loss of nuclear p21(Cip1/WAF1) during neoplastic progression to metastasis in gamma-irradiated p21 hemizygous mice. Exp Mol Pathol. 2007 Jun; 82(3):234-44.
  51. Pal T, Permuth-Wey J, Kapoor R, Cantor A, Sutphen R. Improved survival in BRCA2 carriers with ovarian cancer. Fam Cancer. 2007; 6(1):113-9.
  52. Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann Surg Oncol. 2007 Feb; 14(2):869-84.
  53. Heysek RV, Gwede CK, Torres-Roca J, Cantor A, Kelley S, Saini AS, Pow-Sang J. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy. 2006 Oct-Dec; 5(4):244-50.
  54. Laronga C, Hasson D, Hoover S, Cox J, Cantor A, Cox C, Carter WB. Paget's disease in the era of sentinel lymph node biopsy. Am J Surg. 2006 Oct; 192(4):481-3.
  55. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006 Oct 10; 24(29):4731-7.
  56. Torres-Roca JF, Cantor AB, Shukla S, Montejo ME, Friedland J, Seigne JD, Heysek R, Pow-Sang J. Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience. Urol Oncol. 2006 Sep-Oct; 24(5):384-90.
  57. Simon GR, Lush RM, Gump J, Tetteh L, Williams C, Cantor A, Antonia S, Garrett C, Rocha-Lima C, Fishman M, Sullivan DM, Munster PN. Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial. Mol Cancer Ther. 2006 Aug; 5(8):2130-7.
  58. Andrews S, Robinson L, Cantor A, DeConti RC. Survival after surgical resection of isolated pulmonary metastases from malignant melanoma. Cancer Control. 2006 Jul; 13(3):218-23.
  59. Wu JJ, Cantor A, Moscinski LC. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid. Leuk Res. 2007 Jan; 31(1):49-57.
  60. Osborne D, Pappas E, Alexander G, Boe B, Cantor AB, Rosemurgy A, Zervos E. A complication-free course ensures a survival advantage in patients after regional therapy for metastatic colorectal cancer. Am Surg. 2006 Jun; 72(6):505-10.
  61. Cox C, White L, Allred N, Meyers M, Dickson D, Dupont E, Cantor A, Ly Q, Dessureault S, King J, Nicosia S, Vrcel V, Diaz N. Survival outcomes in node-negative breast cancer patients evaluated with complete axillary node dissection versus sentinel lymph node biopsy. Ann Surg Oncol. 2006 May; 13(5):708-11.
  62. Zheng Z, Cantor A, Bepler G. A global genome damage score predictive of lung cancer patients outcome. Oncogene. 2006 Jul 27; 25(32):4491-4.
  63. Martino MA, Borges E, Williamson E, Siegfried S, Cantor AB, Lancaster J, Roberts WS, Hoffman MS. Pulmonary embolism after major abdominal surgery in gynecologic oncology. Obstet Gynecol. 2006 Mar; 107(3):666-71.
  64. Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM. Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res. 2006 Jan 15; 12(2):523-8.
  65. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006 Jan; 13(1):72-8.
  66. Diaz N, Minton S, Cox C, Bowman T, Gritsko T, Garcia R, Eweis I, Wloch M, Livingston S, Seijo E, Cantor A, Lee JH, Beam CA, Sullivan D, Jove R, Muro-Cacho CA. Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res. 2006 Jan 1; 12(1):20-8.
  67. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005 Dec 15; 104(12):2807-16.
  68. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res. 2005 Dec 1; 11(23):8288-94.
  69. Gwede CK, Johnsson DJ, Roberts C, Cantor AB. Burnout in clinical research coordinators in the United States. Oncol Nurs Forum. 2005 Nov; 32(6):1123-30.
  70. Ramnath N, Sommers E, Robinson L, Nwogu C, Sharma A, Cantor A, Bepler G. Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer. Chest. 2005 Nov; 128(5):3467-74.
  71. Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB. Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer. 2005 Oct 1; 104(7):1381-90.
  72. Torres-Roca JF, Eschrich S, Zhao H, Bloom G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, Jove R, Yeatman T. Prediction of radiation sensitivity using a gene expression classifier. Cancer Res. 2005 Aug 15; 65(16):7169-76.
  73. Martino MA, Williamson E, Siegfried S, Cardosi RJ, Cantor AB, Hoffman MS, Fiorica JV. Diagnosing pulmonary embolism: experience with spiral CT pulmonary angiography in gynecologic oncology. Gynecol Oncol. 2005 Aug; 98(2):289-93.
  74. Vila H, Smith RA, Augustyniak MJ, Nagi PA, Soto RG, Ross TW, Cantor AB, Strickland JM, Miguel RV. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg. 2005 Aug; 101(2):474-80, table of contents.
  75. Kumar NB, Riccardi D, Cantor A, Dalton K, Allen K. A case-control study evaluating the association of purposeful physical activity, body fat distribution, and steroid hormones on premenopausal breast cancer risk. Breast J. 2005 Jul-Aug; 11(4):266-72.
  76. Cantor AB. GATA transcription factors in hematologic disease. Int J Hematol. 2005 Jun; 81(5):378-84.
  77. Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhøffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol. 2005 May 20; 23(15):3526-35.
  78. Báez A, Cantor A, Fonseca S, Marcos-Martinez M, Mathews LA, Muro-Cacho CA, Muñoz-Antonia T. Differences in Smad4 expression in human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck squamous cell carcinoma. Clin Cancer Res. 2005 May 1; 11(9):3191-7.
  79. Ferraro B, Bepler G, Sharma S, Cantor A, Haura EB. EGR1 predicts PTEN and survival in patients with non-small-cell lung cancer. J Clin Oncol. 2005 Mar 20; 23(9):1921-6.
  80. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 2005 Mar; 127(3):978-83.
  81. Cox C, Centeno B, Dickson D, Clark J, Nicosia S, Dupont E, Greenberg H, Stowell N, White L, Patel J, Furman B, Cantor A, Hakam A, Ahmad N, Diaz N, King J. Accuracy of intraoperative imprint cytology for sentinel lymph node evaluation in the treatment of breast carcinoma. Cancer. 2005 Feb 25; 105(1):13-20.
  82. Soares HP, Kumar A, Daniels S, Swann S, Cantor A, Hozo I, Clark M, Serdarevic F, Gwede C, Trotti A, Djulbegovic B. Evaluation of new treatments in radiation oncology: are they better than standard treatments? JAMA. 2005 Feb 23; 293(8):970-8.
  83. Bepler G, Zheng Z, Gautam A, Sharma S, Cantor A, Sharma A, Cress WD, Kim YC, Rosell R, McBride C, Robinson L, Sommers E, Haura E. Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. Lung Cancer. 2005 Feb; 47(2):183-92.
  84. Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005; 4(1):34-44.
  85. Cantor AB, Orkin SH. Coregulation of GATA factors by the Friend of GATA (FOG) family of multitype zinc finger proteins. Semin Cell Dev Biol. 2005 Feb; 16(1):117-28.
  86. Brandon TH, Meade CD, Herzog TA, Chirikos TN, Webb MS, Cantor AB. Efficacy and cost-effectiveness of a minimal intervention to prevent smoking relapse: dismantling the effects of amount of content versus contact. J Consult Clin Psychol. 2004 Oct; 72(5):797-808.
  87. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004 Aug; 126(2):347-51.
  88. Sutphen R, Xu Y, Wilbanks GD, Fiorica J, Grendys EC, LaPolla JP, Arango H, Hoffman MS, Martino M, Wakeley K, Griffin D, Blanco RW, Cantor AB, Xiao YJ, Krischer JP. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004 Jul; 13(7):1185-91.
  89. Roetzheim RG, Christman LK, Jacobsen PB, Cantor AB, Schroeder J, Abdulla R, Hunter S, Chirikos TN, Krischer JP. A randomized controlled trial to increase cancer screening among attendees of community health centers. Ann Fam Med. 2004 Jul-Aug; 2(4):294-300.
  90. Bepler G, Sharma S, Cantor A, Gautam A, Haura E, Simon G, Sharma A, Sommers E, Robinson L. RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. J Clin Oncol. 2004 May 15; 22(10):1878-85.
  91. Christman LK, Abdulla R, Jacobsen PB, Cantor AB, Mayhew DY, Thompson KS, Krischer JP, Roetzheim RG. Colorectal cancer screening among a sample of community health center attendees. J Health Care Poor Underserved. 2004 May; 15(2):281-93.
  92. Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R, Pow-Sang J. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004 May 1; 59(2):141-7.
  93. Carrion R, Arap S, Corcione G, Ferreyra U, Neyra Argote G, Cantor A, Seigne J, Lockhart J. A multi-institutional study of orthotopic neobladders: functional results in men and women. BJU Int. 2004 Apr; 93(6):803-6.
  94. Nasir A, Catalano E, Calafati S, Cantor A, Kaiser HE, Coppola D. Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. In Vivo. 2004 Mar-Apr; 18(2):189-95.
  95. Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood. 2004 May 1; 103(9):3271-7.
  96. Pal S, Cantor AB, Johnson KD, Moran TB, Boyer ME, Orkin SH, Bresnick EH. Coregulator-dependent facilitation of chromatin occupancy by GATA-1. Proc Natl Acad Sci U S A. 2004 Jan 27; 101(4):980-5.
  97. Kumar N, Allen KA, Riccardi D, Bercu BB, Cantor A, Minton S, Balducci L, Jacobsen PB. Fatigue, weight gain, lethargy and amenorrhea in breast cancer patients on chemotherapy: is subclinical hypothyroidism the culprit? Breast Cancer Res Treat. 2004 Jan; 83(2):149-59.
  98. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as colon cancer tumor progression marker. C R Biol. 2003 Oct-Nov; 326(10-11):1041-3.
  99. Djulbegovic B, Cantor A, Clarke M. The importance of preservation of the ethical principle of equipoise in the design of clinical trials: relative impact of the methodological quality domains on the treatment effect in randomized controlled trials. Account Res. 2003 Oct-Dec; 10(4):301-15.
  100. Simon GR, Ruckdeschel JC, Williams C, Cantor A, Chiappori A, Rocha Lima CM, Antonia S, Haura E, Wagner H, Robinson L, Sommers E, Alberts M, Bepler G. Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution. Cancer Control. 2003 Sep-Oct; 10(5):388-95.
  101. Vila H, Soto R, Cantor AB, Mackey D. Comparative outcomes analysis of procedures performed in physician offices and ambulatory surgery centers. Arch Surg. 2003 Sep; 138(9):991-5.
  102. Naidu KA, Fu ES, Sutton ET, Prockop LD, Cantor A. The therapeutic effects of epidural intercellular adhesion molecule-1 monoclonal antibody in a rabbit model: involvement of the intercellular adhesion molecule-1 pathway in spinal cord ischemia. Anesth Analg. 2003 Sep; 97(3):857-62.
  103. Iwasaki H, Mizuno S, Wells RA, Cantor AB, Watanabe S, Akashi K. GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity. 2003 Sep; 19(3):451-62.
  104. Extermann M, Albrand G, Chen H, Zanetta S, Schonwetter R, Zulian GB, Cantor A, Droz JP. Are older French patients as willing as older American patients to undertake chemotherapy? J Clin Oncol. 2003 Sep 1; 21(17):3214-9.
  105. Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res. 2003 Jun 15; 63(12):3021-5.
  106. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 2003 Jun; 40(3):267-79.
  107. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, Sebti SM. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003 Mar 15; 63(6):1270-9.
  108. Chen H, Cantor A, Meyer J, Beth Corcoran M, Grendys E, Cavanaugh D, Antonek S, Camarata A, Haley W, Balducci L, Extermann M. Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer. 2003 Feb 15; 97(4):1107-14.
  109. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene. 2002 Dec 5; 21(55):8486-97.
  110. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002 Nov 15; 62(22):6659-66.
  111. Jakub JW, Diaz NM, Ebert MD, Cantor A, Reintgen DS, Dupont EL, Shons AR, Cox CE. Completion axillary lymph node dissection minimizes the likelihood of false negatives for patients with invasive breast carcinoma and cytokeratin positive only sentinel lymph nodes. Am J Surg. 2002 Oct; 184(4):302-6.
  112. Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor A, Extermann M, Mellor AL, Munn DH, Antonia SJ. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002 Sep 10; 101(2):151-5.
  113. Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002 Sep-Oct; 10(5):248-55.
  114. Extermann M, Chen H, Cantor AB, Corcoran MB, Meyer J, Grendys E, Cavanaugh D, Antonek S, Camarata A, Haley WE, Balducci L. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002 Jul; 38(11):1466-73.
  115. Chang AN, Cantor AB, Fujiwara Y, Lodish MB, Droho S, Crispino JD, Orkin SH. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci U S A. 2002 Jul 9; 99(14):9237-42.
  116. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, Orkin SH. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med. 2002 Jun 3; 195(11):1387-95.
  117. Sharkey J, Cantor A, Solc Z, Huff W, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep. 2002 Jun; 3(3):250-7.
  118. Cantor AB, Katz SG, Orkin SH. Distinct domains of the GATA-1 cofactor FOG-1 differentially influence erythroid versus megakaryocytic maturation. Mol Cell Biol. 2002 Jun; 22(12):4268-79.
  119. Cantor AB, Orkin SH. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene. 2002 May 13; 21(21):3368-76.
  120. Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M, Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002 May; 167(5):1995-2000.
  121. Katz SG, Cantor AB, Orkin SH. Interaction between FOG-1 and the corepressor C-terminal binding protein is dispensable for normal erythropoiesis in vivo. Mol Cell Biol. 2002 May; 22(9):3121-8.
  122. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst. 2002 Apr 3; 94(7):513-21.
  123. Levy O, Bourquin JP, McQueen A, Cantor AB, Lachenauer C, Malley R. Fatal disseminated Candida lusitaniae infection in an infant with chronic granulomatous disease. Pediatr Infect Dis J. 2002 Mar; 21(3):262-4.
  124. Cox CE, Dupont E, Whitehead GF, Ebert MD, Nguyen K, Peltz ES, Peckham D, Cantor A, Reintgen DS. Age and body mass index may increase the chance of failure in sentinel lymph node biopsy for women with breast cancer. Breast J. 2002 Mar-Apr; 8(2):88-91.
  125. Kumar NB, Cantor A, Allen K, Riccardi D, Cox CE. The specific role of isoflavones on estrogen metabolism in premenopausal women. Cancer. 2002 Feb 15; 94(4):1166-74.
  126. Zhou J, Nong L, Wloch M, Cantor A, Mulshine JL, Tockman MS. Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50.
  127. Cox CE, Salud CJ, Cantor A, Bass SS, Peltz ES, Ebert MD, Nguyen K, Reintgen DS. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg. 2001 Dec; 193(6):593-600.
  128. Cantor AB, Orkin SH. Hematopoietic development: a balancing act. Curr Opin Genet Dev. 2001 Oct; 11(5):513-9.
  129. Carver JD, Benford VJ, Han B, Cantor AB. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res Bull. 2001 Sep 15; 56(2):79-85.
  130. Cantor AB. Projecting the standard error of the Kaplan-Meier estimator. Stat Med. 2001 Jul 30; 20(14):2091-7.
  131. Cox CE, Nguyen K, Gray RJ, Salud C, Ku NN, Dupont E, Hutson L, Peltz E, Whitehead G, Reintgen D, Cantor A. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001 Jun; 67(6):513-9; discussion 519-21.
  132. Zachariah B, Jacob SS, Gwede C, Cantor A, Patil J, Casey L, Zachariah AB. Effect of fractionated regional external beam radiotherapy on peripheral blood cell count. Int J Radiat Oncol Biol Phys. 2001 Jun 1; 50(2):465-72.
  133. Kamath VJ, Giuliano R, Dauway EL, Cantor A, Berman C, Ku NN, Cox CE, Reintgen DS. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg. 2001 Jun; 136(6):688-92.
  134. Dupont E, Cox C, Shivers S, Salud C, Nguyen K, Cantor A, Reintgen D. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res. 2001 May 1; 97(1):92-6.
  135. Cherpelis BS, Haddad F, Messina J, Cantor AB, Fitzmorris K, Reintgen DS, Fenske NA, Glass LF. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas. J Am Acad Dermatol. 2001 May; 44(5):762-6.
  136. Avino A, Johnson B, Bandyk D, Back M, Roth S, Kudryk B, Cantor A. Does prosthetic covering of nitinol stents alter healing characteristics or hemodynamics? J Endovasc Ther. 2000 Dec; 7(6):469-78.
  137. Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM. Loss of p21WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene. 2000 Nov 9; 19(47):5338-47.
  138. Gal RL, Gal TJ, Klotch DW, Cantor AB. Risk factors associated with hypothyroidism after laryngectomy. Otolaryngol Head Neck Surg. 2000 Sep; 123(3):211-7.
  139. Djulbegovic B, Lacevic M, Cantor A, Fields KK, Bennett CL, Adams JR, Kuderer NM, Lyman GH. The uncertainty principle and industry-sponsored research. Lancet. 2000 Aug 19; 356(9230):635-8.
  140. Muro-Cacho CA, Cantor AB, Morgan M. Prognostic factors in malignant gastrointestinal stromal tumors. Ann Clin Lab Sci. 2000 Jul; 30(3):239-47.
  141. Kumar NB, Cantor A, Allen K, Cox CE. Android obesity at diagnosis and breast carcinoma survival: Evaluation of the effects of anthropometric variables at diagnosis, including body composition and body fat distribution and weight gain during life span,and survival from breast carcinoma. Cancer. 2000 Jun 15; 88(12):2751-7.
  142. Teng S, Dupont E, McCann C, Wang J, Bolano M, Durand K, Peltz E, Bass SS, Cantor A, Ku NN, Cox CE. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg. 2000 Jun; 66(6):574-8.
  143. Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R, Solc Z, Huff W, Cantor A, Steele J, Webster C, Donohue M. Evolution of techniques for ultrasound-guided palladium 103 brachytherapy in 950 patients with prostate cancer. Tech Urol. 2000 Jun; 6(2):128-34.
  144. Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia. 2000 May; 14(5):830-40.
  145. Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Rabinowitz R, Steele J, Webster C, Donohue M, Solc Z, Huff W, Cantor A. Minimally invasive treatment for localized adenocarcinoma of the prostate: review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol. 2000 May; 14(4):343-50.
  146. Mora LB, Diaz JI, Cantor AB, Nicosia SV. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression. Ann Clin Lab Sci. 1999 Oct-Dec; 29(4):308-15.
  147. Pu LL, Cruse CW, Wells KE, Cantor A, Glass LF, Messina JL, Reintgen DS. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma of the lower extremity. Plast Reconstr Surg. 1999 Sep; 104(4):964-9.
  148. Vyas P, McDevitt MA, Cantor AB, Katz SG, Fujiwara Y, Orkin SH. Different sequence requirements for expression in erythroid and megakaryocytic cells within a regulatory element upstream of the GATA-1 gene. Development. 1999 Jun; 126(12):2799-811.
  149. Diaz JI, Mora LB, Austin PF, Muro-Cacho CA, Cantor AB, Nicosia SV, Pow-Sang JM. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumoral cell proliferation. Urology. 1999 May; 53(5):931-8.
  150. Tevosian SG, Deconinck AE, Cantor AB, Rieff HI, Fujiwara Y, Corfas G, Orkin SH. FOG-2: A novel GATA-family cofactor related to multitype zinc-finger proteins Friend of GATA-1 and U-shaped. Proc Natl Acad Sci U S A. 1999 Feb 2; 96(3):950-5.
  151. Avino AJ, Bandyk DF, Gonsalves AJ, Johnson BL, Black TJ, Zwiebel BR, Rahaim MJ, Cantor A. Surgical and endovascular intervention for infrainguinal vein graft stenosis. J Vasc Surg. 1999 Jan; 29(1):60-70; discussion 70-1.
  152. Cantor A, Goldfarb B, Mai O, Battler A. Ischemia detection in women: the diagnostic value of exercise QRS duration changes. J Electrocardiol. 1998 Oct; 31(4):271-7.
  153. Velthuizen RP, Heine JJ, Cantor AB, Lin H, Fletcher LM, Clarke LP. Review and evaluation of MRI nonuniformity corrections for brain tumor response measurements. Med Phys. 1998 Sep; 25(9):1655-66.
  154. Trotti A, Johnson DJ, Gwede C, Casey L, Sauder B, Cantor A, Pearlman J. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI) Int J Radiat Oncol Biol Phys. 1998 Sep 1; 42(2):257-61.
  155. Coppola D, Hyacinthe M, Fu L, Cantor AB, Karl R, Marcet J, Cooper DL, Nicosia SV, Cooper HS. CD44V6 expression in human colorectal carcinoma. Hum Pathol. 1998 Jun; 29(6):627-35.
  156. Brobeil A, Berman C, Cruse CW, De Conti R, Cantor A, Lyman GH, Joseph E, Rapaport D, Wells K, Reintgen DS. Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma. Ann Surg Oncol. 1998 Jun; 5(4):376-83.
  157. Sharkey J, Chovnick SD, Behar RJ, Perez R, Otheguy J, Solc Z, Huff W, Cantor A. Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients. Urology. 1998 May; 51(5):796-803.
  158. Pratt CB, Maurer HM, Gieser P, Salzberg A, Rao BN, Parham D, Thomas PR, Marcus RB, Cantor A, Pick T, Green D, Neff J, Jenkins JJ. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998 Apr; 30(4):201-9.
  159. Trotti A, Klotch D, Endicott J, Ridley M, Cantor A. Postoperative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. Head Neck. 1998 Mar; 20(2):119-23.
  160. Cantor A, Goldfarb B, Aszodi A, Battler A. Ischemia detection after myocardial infarction: diagnostic value of exercise-induced QRS duration changes evaluated by a new computerized method. J Electrocardiol. 1998 Jan; 31(1):9-15.
  161. Cantor A, Goldfarb B, Aszodi A, Battler A. QRS prolongation measured by a new computerized method: a sensitive marker for detecting exercise-induced ischemia. Cardiology. 1997 Sep-Oct; 88(5):446-52.
  162. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, Ternberg JL, Behm FG, Wharam MD, Chauvenet AR. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1997 Aug; 15(8):2769-79.
  163. Kumar NB, Allen K, Cantor A, Cox CE, Greenberg H, Shah S, Lyman GH. Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res Treat. 1997 Jun; 44(2):135-43.
  164. Yeatman TJ, Lyman GH, Smith SK, Reintgen DS, Cantor AB, Cox CE. Bilaterality and recurrence rates for lobular breast cancer: considerations for treatment. Ann Surg Oncol. 1997 Apr-May; 4(3):198-202.
  165. White MH, Anaissie EJ, Kusne S, Wingard JR, Hiemenz JW, Cantor A, Gurwith M, Du Mond C, Mamelok RD, Bowden RA. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis. 1997 Apr; 24(4):635-42.
  166. Bowman LC, Castleberry RP, Cantor A, Joshi V, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997 Mar 5; 89(5):373-80.
  167. Kamath D, Cantor AB, Glass F, Fenske N, Cruse CW, Wells K, Rapaport D, DeConti R, Messina J, Reintgen D. Florida's undeclared epidemic: malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):161-5.
  168. Brobeil A, Rapaport D, Wells K, Cruse CW, Glass F, Fenske N, Albertini J, Miliotis G, Messina J, DeConti R, Berman C, Shons A, Cantor A, Reintgen DS. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997 Jan; 4(1):19-23.
  169. Eller DA, Homsy YL, Austin PF, Tanguay S, Cantor A. Spot urine osmolality, age and bladder capacity as predictors of response to desmopressin in nocturnal enuresis. Scand J Urol Nephrol Suppl. 1997; 183:41-5.
  170. Alvarado CS, Kretschmar C, Joshi VV, Toledano S, Cantor A, Strother D, Nitschke R, Castleberry RP. Chemotherapy for patients with recurrent or refractory neuroblastoma: a POG Phase II study. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):62-7.
  171. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, Shivers S, Berman C, Wells K, Rapaport D, Shons A, Horton J, Greenberg H, Nicosia S, Clark R, Cantor A, Reintgen DS. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996 Dec 11; 276(22):1818-22.
  172. Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL. Peptide amidating activity in human bronchoalveolar lavage fluid. Lung Cancer. 1996 Jun; 14(2-3):239-51.
  173. Joshi VV, Rao PV, Cantor AB, Altshuler G, Shuster JJ, Castleberry RP. Modified histologic grading of neuroblastomas by replacement of mitotic rate with mitosis karyorrhexis index. A clinicopathologic study of 223 cases from the Pediatric Oncology Group. Cancer. 1996 Apr 15; 77(8):1582-8.
  174. Cantor AB. Power calculation for the log rank test using historical data. Control Clin Trials. 1996 Apr; 17(2):111-6.
  175. Cantor AB, Krischer JP, Cuthbertson DD, Schatz DA, Riley WJ, Malone J, Schwartz S, Quattrin T, Maclaren NK. Age and family relationship accentuate the risk of insulin-dependent diabetes mellitus (IDDM) in relatives of patients with IDDM. J Clin Endocrinol Metab. 1995 Dec; 80(12):3739-43.
  176. Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen DS, Miller MS, Ku NN, Baekey PA, Cox CE. Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995 Oct; 222(4):549-59; discussion 559-61.
  177. Parham DM, Webber BL, Jenkins JJ, Cantor AB, Maurer HM. Nonrhabdomyosarcomatous soft tissue sarcomas of childhood: formulation of a simplified system for grading. Mod Pathol. 1995 Sep; 8(7):705-10.
  178. Cantor AB. A test of the association of a time-dependent state variable to survival. Comput Methods Programs Biomed. 1995 Feb; 46(2):101-5.
  179. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS, Holbrook T, Link MP. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995 Feb; 24(2):87-92.
  180. Castleberry RP, Cantor AB, Green AA, Joshi V, Berkow RL, Buchanan GR, Leventhal B, Mahoney DH, Smith EI, Hayes FA. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1994 Aug; 12(8):1616-20.
  181. Mendenhall NP, Cantor AB, Barré DM, Lynch JW, Million RR. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol. 1994 Jun; 17(3):189-95.
  182. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med. 1993 Mar 25; 328(12):847-54.
  183. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1993 Jan; 11(1):96-9.
  184. Cantor AB, Baranski TJ, Kornfeld S. Lysosomal enzyme phosphorylation. II. Protein recognition determinants in either lobe of procathepsin D are sufficient for phosphorylation of both the amino and carboxyl lobe oligosaccharides. J Biol Chem. 1992 Nov 15; 267(32):23349-56.
  185. Cantor AB, Kornfeld S. Phosphorylation of Asn-linked oligosaccharides located at novel sites on the lysosomal enzyme cathepsin D. J Biol Chem. 1992 Nov 15; 267(32):23357-63.
  186. Baranski TJ, Cantor AB, Kornfeld S. Lysosomal enzyme phosphorylation. I. Protein recognition determinants in both lobes of procathepsin D mediate its interaction with UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. J Biol Chem. 1992 Nov 15; 267(32):23342-8.
  187. Cantor AB, Kornfeld S. A method for [3H]mannose labeling of Asn-linked oligosaccharides on recombinant glycoproteins synthesized in Xenopus oocytes. Anal Biochem. 1992 Sep; 205(2):220-6.
  188. Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, Vogelstein B, Cantor AB, Look AT, Brodeur GM. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992 Apr 1; 52(7):1780-5.
  189. Weiner MA, Leventhal BG, Marcus R, Brecher M, Ternberg J, Behm FG, Cantor A, Wharam M, Chauvenet A. Intensive chemotherapy and low-dose radiotherapy for the treatment of advanced-stage Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol. 1991 Sep; 9(9):1591-8.
  190. Shuster JJ, Cantor AB, McWilliams N, Pole JG, Castleberry RP, Marcus R, Pick T, Smith EI, Hayes FA. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol. 1991 Jun; 9(6):1045-9.
  191. Malatesta VJ, Chambless DL, Pollack M, Cantor A. Widowhood, sexuality and aging: a life span analysis. J Sex Marital Ther. 1988; 14(1):49-62.
  192. Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell. 1987 Jan 30; 48(2):185-91.
  193. Cantor A, Schobert W. The Coagulation and Sterilization of Culture Media. J Bacteriol. 1943 Aug; 46(2):203-4.
  194. Cantor A, Shelanski HA, Willard CY. A Microscopic Alkali-Solubility Test for the Identification of Gonococcus Colonies. J Bacteriol. 1942 Aug; 44(2):237-40.
To schedule an appointment: Call 617-919-2026 or Request an Appointment

Locations

We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close